A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

NCT06326047 · Completed

Last updated 2026-05-28

This study is testing different doses of the medicine NN0519-0130 to see how well they lower blood sugar in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 299 people

Who can join Ages 18–75 · all sexes

Timeline Started 2024-03 · est. completion 2025-10

Where 94 sites · Australia, Canada, India, Japan, South Africa, South Korea, United States

What this study is testing ClinicalTrials.gov NCT06326047 ↗

Description as written by the study sponsor.

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

Treatments tested

NNC0519-0130 Drug

NNC0519-0130 will be administered subcutaneously.
Placebo Drug

Placebo will be administered subcutaneously.
Trizepatide Drug

Trizepatide will be administered subcutaneously.

Main thing measured	Change in Glycated haemoglobin (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06326047 ↗